- Home
- OIM vs ACRS Comparison
OIM vs ACRS Comparison
Compare OIM & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OIM | ACRS |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.0M | 311.0M |
| IPO Year | 2026 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OIM | ACRS |
|---|---|---|
| Price | $10.02 | $4.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.20 |
| AVG Volume (30 Days) | 7.6K | ★ 1.3M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.96 | $1.27 |
| 52 Week High | $10.10 | $5.15 |
Technical Indicators
Market Signals| Indicator | OIM | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 52.51 |
| Support Level | $9.96 | $4.08 |
| Resistance Level | $10.05 | $4.56 |
| Average True Range (ATR) | 0.01 | 0.26 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 50.00 | 35.33 |
Price Performance
Historical ComparisonAbout OIM OneIM Acquisition Corp. Class A Ordinary Shares
OneIM Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.